🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesRemission of T2DM on GLP-1 — need advice

Remission of T2DM on GLP-1 — need advice

sean_dublin Sat, Oct 19, 2024 at 2:55 AM 27 replies 2,227 viewsPage 1 of 6
This thread is more than 19 months old. Information may be outdated. Consider searching for more recent discussions.
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Oct 19, 2024 at 2:55 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very little. The improvement on this class comes from two directions — direct glucose-dependent insulin secretion and glucagon suppression, plus the indirect effect of weight loss on insulin sensitivity — and the second continues after the first has plateaued.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What would genuinely help is knowing why A1C lags the way it does, and what to look at in the meantime if you want to know sooner. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
16 11hannah_MT, Dr.SportsMedIN, amy_econ_NJ and 13 others
Reply Quote Save Share Report
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Oct 19, 2024 at 3:08 AM#2
sean_dublin said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.8 (insulin resistant) → Current = 1.2 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

Last edited: Oct 19, 2024 at 7:08 AM
15 10newstart_MO, mia_MS2, LeilaHI and 12 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Oct 19, 2024 at 3:21 AM#3
sean_dublin said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 35% to 21%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

14 9HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 11 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Oct 19, 2024 at 3:34 AM#4
Dr.MetabolicMD said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 35% to 21%.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

13 8ricardo_MIA, BrianDallas92, labquiet_amy and 10 others
Reply Quote Save Share Report
alex_tucson
Member
567
2,345
May 2024
Tucson, AZ
Oct 19, 2024 at 4:44 AM#5
mike.trainer_LA said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

This matches mine closely enough to be worth saying so out loud. I had assumed I was the exception until I read this.

12 7FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 9 others
Reply Quote Save Share Report
1236

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register